These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31422033)

  • 21. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.
    Mansoor S; Yerian L; Kohli R; Xanthakos S; Angulo P; Ling S; Lopez R; Christine CK; Feldstein AE; Alkhouri N
    Dig Dis Sci; 2015 May; 60(5):1440-7. PubMed ID: 25540086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease.
    Yang M; Jiang L; Wang Y; Li X; Zou Z; Han T; Nan Y; Lu F; Zhao J
    J Gastrointestin Liver Dis; 2019 Sep; 28(3):289-296. PubMed ID: 31517325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.
    Joo SK; Kim W; Kim D; Kim JH; Oh S; Lee KL; Chang MS; Jung YJ; So YH; Lee MS; Bae JM; Kim BG
    Liver Int; 2018 Feb; 38(2):331-341. PubMed ID: 28796410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.
    Canivet CM; Costentin C; Irvine KM; Delamarre A; Lannes A; Sturm N; Oberti F; Patel PJ; Decaens T; Irles-Depé M; Fouchard I; Hermabessière P; Roux M; Barthelon J; Calès P; Powell EE; de Ledinghen V; Boursier J
    Hepatology; 2023 Mar; 77(3):920-930. PubMed ID: 35822302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease.
    Li Q; Lu C; Li W; Huang Y; Chen L
    Oncotarget; 2017 Apr; 8(17):28641-28649. PubMed ID: 28415736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease.
    Shima T; Sakai K; Oya H; Katayama T; Mitsumoto Y; Mizuno M; Kanbara Y; Okanoue T
    J Gastroenterol; 2020 Jan; 55(1):100-112. PubMed ID: 31538241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.
    Ciardullo S; Muraca E; Perra S; Bianconi E; Zerbini F; Oltolini A; Cannistraci R; Parmeggiani P; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
    BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32049637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Single Test Combining Blood Markers and Elastography is More Accurate Than Other Fibrosis Tests in the Main Causes of Chronic Liver Diseases.
    Ducancelle A; Leroy V; Vergniol J; Sturm N; Le Bail B; Zarski JP; Nguyen Khac E; Salmon D; de Ledinghen V; Calès P
    J Clin Gastroenterol; 2017 Aug; 51(7):639-649. PubMed ID: 28692443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease.
    Dincses E; Yilmaz Y
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1149-53. PubMed ID: 26049712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease.
    Caussy C; Ajmera VH; Puri P; Hsu CL; Bassirian S; Mgdsyan M; Singh S; Faulkner C; Valasek MA; Rizo E; Richards L; Brenner DA; Sirlin CB; Sanyal AJ; Loomba R
    Gut; 2019 Oct; 68(10):1884-1892. PubMed ID: 30567742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
    Siddiqui MS; Yamada G; Vuppalanchi R; Van Natta M; Loomba R; Guy C; Brandman D; Tonascia J; Chalasani N; Neuschwander-Tetri B; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1877-1885.e5. PubMed ID: 30616027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation study of systems for noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in Latin population.
    Pérez-Gutiérrez OZ; Hernández-Rocha C; Candia-Balboa RA; Arrese MA; Benítez C; Brizuela-Alcántara DC; Méndez-Sánchez N; Uribe M; Chávez-Tapia NC
    Ann Hepatol; 2013; 12(3):416-24. PubMed ID: 23619258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic screening for advanced liver fibrosis in patients with coronary artery disease: The CORONASH study.
    Thévenot T; Vendeville S; Weil D; Akkouche L; Calame P; Canivet CM; Vanlemmens C; Richou C; Cervoni JP; Seronde MF; Di Martino V; Boursier J
    PLoS One; 2022; 17(5):e0266965. PubMed ID: 35617294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.
    McPherson S; Hardy T; Dufour JF; Petta S; Romero-Gomez M; Allison M; Oliveira CP; Francque S; Van Gaal L; Schattenberg JM; Tiniakos D; Burt A; Bugianesi E; Ratziu V; Day CP; Anstee QM
    Am J Gastroenterol; 2017 May; 112(5):740-751. PubMed ID: 27725647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
    McPherson S; Stewart SF; Henderson E; Burt AD; Day CP
    Gut; 2010 Sep; 59(9):1265-9. PubMed ID: 20801772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility and limitations of APRI and FIB4 to predict staging in a cohort of nonselected outpatients with hepatitis C.
    de Oliveira AC; El-Bacha I; Vianna MV; Parise ER
    Ann Hepatol; 2016; 15(3):326-32. PubMed ID: 27049486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between telomere length and hepatic fibrosis in non-alcoholic fatty liver disease.
    Shin HK; Park JH; Yu JH; Jin YJ; Suh YJ; Lee JW; Kim W;
    Sci Rep; 2021 Sep; 11(1):18004. PubMed ID: 34504179
    [TBL] [Abstract][Full Text] [Related]  

  • 39.  Most overweight and obese Indian children have nonalcoholic fatty liver disease.
    Pawar SV; Zanwar VG; Choksey AS; Mohite AR; Jain SS; Surude RG; Contractor QQ; Rathi PM; Verma RU; Varthakavi PK
    Ann Hepatol; 2016 Nov-Dec 2016; 15(6):853-861. PubMed ID: 27740518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection.
    Yosry A; Fouad R; Alem SA; Elsharkawy A; El-Sayed M; Asem N; Hassan E; Ismail A; Esmat G
    Arab J Gastroenterol; 2016 Jun; 17(2):78-83. PubMed ID: 27353055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.